ORGO
Organogenesis Holdings Inc.
Price Chart
Latest Quote
$2.43
-0.01 (-0.41%)
Current Price
| Previous Close | $2.44 |
| Open | $2.44 |
| Day High | $2.48 |
| Day Low | $2.38 |
| Volume | 529,135 |
Stock Information
| Shares Outstanding | 128.67M |
| Total Debt | $70.86M |
| Cash Equivalents | $91.38M |
| Revenue | $514.70M |
| Net Income | $-14.55M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $312.68M |
| EPS (TTM) | $-0.12 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $428.95M |
| Sales | $514.70M |
| Income | $-14.55M |
| Book/sh | $1.90 |
| Cash/sh | $0.71 |
| Employees | 854 |
Financial Ratios
| Quick Ratio | 2.74 |
| Current Ratio | 3.53 |
| Debt/Eq | 18.58 |
Returns & Margins
| ROA | 2.12% |
| ROE | 0.73% |
| Gross Margin | 73.89% |
| Operating Margin | -174.69% |
| Profit Margin | 0.53% |
Ownership
| Insider Ownership | 47.46% |
| Institutional Ownership | 49.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.84 |
| P/S | 0.61 |
| P/B | 1.28 |
Analyst Data
| Recommendation | none |
| Target Price | $3.00 |
Technical Indicators
| SMA20 | $2.45 |
| SMA50 | $2.46 |
| SMA200 | $3.74 |
| RSI | 53.68 |
| ATR | 0.1269 |
| Shares Float | 57.38M |
| Short Float | 16.25% |
| Short Ratio | 8.66 |
| Volatility | 1.33 |
| Rel Volume | 0.65 |
Performance History
| Week | +3.85% |
| Month | -4.71% |
| Quarter | +1.67% |
| 6 Months | -53.89% |
| YTD | -47.57% |
| Year | -25.69% |
| 3 Years | -43.49% |
| 5 Years | -84.76% |
| 10 Years | -75.08% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $2.43 | 539,700 |
| 2026-06-18 | $2.44 | 681,800 |
| 2026-06-17 | $2.34 | 758,600 |
| 2026-06-16 | $2.40 | 501,000 |
| 2026-06-15 | $2.41 | 1,123,700 |
| 2026-06-12 | $2.34 | 760,800 |
| 2026-06-11 | $2.38 | 834,100 |
| 2026-06-10 | $2.47 | 503,200 |
| 2026-06-09 | $2.48 | 519,400 |
| 2026-06-08 | $2.38 | 438,200 |
| 2026-06-05 | $2.42 | 673,600 |
| 2026-06-04 | $2.48 | 1,187,500 |
| 2026-06-03 | $2.33 | 809,300 |
| 2026-06-02 | $2.24 | 878,700 |
| 2026-06-01 | $2.36 | 956,400 |
| 2026-05-29 | $2.57 | 928,900 |
| 2026-05-28 | $2.62 | 1,548,700 |
| 2026-05-27 | $2.66 | 1,986,500 |
| 2026-05-26 | $2.66 | 584,400 |
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
đ° Latest News
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update
Insider Monkey âĸ 2026-05-20T20:43:53Z
Spotlight On Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-14T18:05:04Z
Undervalued Small Caps With Insider Buying To Watch In May 2026
Simply Wall St. âĸ 2026-05-14T11:39:51Z
Organogenesis (ORGO) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T17:28:17Z
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Organogenesis Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T12:07:15Z
Undiscovered Gems In The US Market Featuring 3 Promising Stocks
Simply Wall St. âĸ 2026-04-15T17:33:38Z
3 Penny Stocks With Market Caps Under $400M To Consider
Simply Wall St. âĸ 2026-04-13T18:05:13Z
Organogenesis Holdings Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-02-27T13:30:00Z
Organogenesis Q4 Earnings Call Highlights
MarketBeat âĸ 2026-02-27T06:12:57Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $137,522,000 | $115,741,000 | $106,481,000 | $105,019,000 |
| Cost Of Revenue | $137,522,000 | $115,741,000 | $106,481,000 | $105,019,000 |
| Total Revenue | $563,030,000 | $482,043,000 | $433,140,000 | $450,893,000 |
| Operating Revenue | $563,030,000 | $482,043,000 | $433,140,000 | $450,893,000 |
| Expenses | ||||
| Total Expenses | $507,161,000 | $460,525,000 | $420,615,000 | $428,589,000 |
| Other Income Expense | $-11,180,000 | $-22,781,000 | $57,000 | $-13,000 |
| Other Non Operating Income Expenses | $-5,000 | $20,000 | $57,000 | $-13,000 |
| Net Non Operating Interest Income Expense | $2,281,000 | $-1,544,000 | $-2,190,000 | $-2,009,000 |
| Operating Expense | $369,639,000 | $344,784,000 | $314,134,000 | $323,570,000 |
| Other Operating Expenses | $-1,139,000 | - | - | - |
| Interest Expense | - | $1,544,000 | $2,190,000 | $2,009,000 |
| Interest Expense Non Operating | - | $1,544,000 | $2,190,000 | $2,009,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $37,032,000 | $861,000 | $4,945,000 | $15,532,000 |
| Net Interest Income | $2,281,000 | $-1,544,000 | $-2,190,000 | $-2,009,000 |
| Interest Income | $2,281,000 | - | - | - |
| Normalized Income | $45,837,900 | $18,873,790 | $4,945,000 | $15,532,000 |
| Net Income From Continuing And Discontinued Operation | $37,032,000 | $861,000 | $4,945,000 | $15,532,000 |
| Total Operating Income As Reported | $44,694,000 | $-1,283,000 | $12,525,000 | $22,304,000 |
| Net Income Common Stockholders | $20,022,000 | $-937,000 | $4,945,000 | $15,532,000 |
| Net Income | $37,032,000 | $861,000 | $4,945,000 | $15,532,000 |
| Net Income Including Noncontrolling Interests | $37,032,000 | $861,000 | $4,945,000 | $15,532,000 |
| Net Income Continuous Operations | $37,032,000 | $861,000 | $4,945,000 | $15,532,000 |
| Pretax Income | $46,970,000 | $-2,807,000 | $10,392,000 | $20,282,000 |
| Special Income Charges | $-11,175,000 | $-22,801,000 | $0 | $0 |
| Interest Income Non Operating | $2,281,000 | - | - | - |
| Operating Income | $55,869,000 | $21,518,000 | $12,525,000 | $22,304,000 |
| Gross Profit | $425,508,000 | $366,302,000 | $326,659,000 | $345,874,000 |
| Per Share | ||||
| Diluted EPS | $0.15 | $-0.01 | $0.04 | $0.12 |
| Basic EPS | $0.16 | $-0.01 | $0.04 | $0.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,369,100 | $-4,788,210 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $93,982,000 | $46,912,000 | $36,031,000 | $40,322,000 |
| Total Unusual Items | $-11,175,000 | $-22,801,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-11,175,000 | $-22,801,000 | $0 | $0 |
| Reconciled Depreciation | $26,938,000 | $25,374,000 | $23,449,000 | $18,031,000 |
| EBITDA (Bullshit earnings) | $82,807,000 | $24,111,000 | $36,031,000 | $40,322,000 |
| EBIT | $55,869,000 | $-1,263,000 | $12,582,000 | $22,291,000 |
| Diluted Average Shares | $130,248,412 | $131,673,278 | $132,746,727 | $132,383,152 |
| Basic Average Shares | $126,738,136 | $131,673,278 | $131,231,317 | $130,070,231 |
| Diluted NI Availto Com Stockholders | $20,022,000 | $-937,000 | $4,945,000 | $15,532,000 |
| Otherunder Preferred Stock Dividend | $6,180,000 | $412,000 | $0 | $0 |
| Preferred Stock Dividends | $10,830,000 | $1,386,000 | - | - |
| Tax Provision | $9,938,000 | $-3,668,000 | $5,447,000 | $4,750,000 |
| Write Off | $0 | $3,959,000 | $0 | $0 |
| Impairment Of Capital Assets | $11,175,000 | $18,842,000 | $0 | $0 |
| Research And Development | $44,542,000 | $50,271,000 | $44,380,000 | $39,762,000 |
| Selling General And Administration | $326,236,000 | $294,513,000 | $269,754,000 | $283,808,000 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $396,001,000 | $344,076,000 | $234,020,000 | $216,108,000 |
| Total Assets | $598,730,000 | $497,886,000 | $460,025,000 | $449,359,000 |
| Total Non Current Assets | $236,542,000 | $211,945,000 | $234,981,000 | $226,750,000 |
| Other Non Current Assets | $9,203,000 | $5,005,000 | $5,990,000 | $1,520,000 |
| Non Current Deferred Assets | $29,962,000 | $39,462,000 | $28,002,000 | $30,014,000 |
| Non Current Deferred Taxes Assets | $29,962,000 | $39,462,000 | $28,002,000 | $30,014,000 |
| Goodwill And Other Intangible Assets | $37,917,000 | $41,240,000 | $44,643,000 | $49,561,000 |
| Other Intangible Assets | $9,145,000 | $12,468,000 | $15,871,000 | $20,789,000 |
| Current Assets | $362,188,000 | $285,941,000 | $225,044,000 | $222,609,000 |
| Other Current Assets | $7,389,000 | $5,249,000 | $5,118,000 | $4,291,000 |
| Assets Held For Sale Current | $2,425,000 | $0 | - | - |
| Restricted Cash | $652,000 | $580,000 | $498,000 | $812,000 |
| Prepaid Assets | $10,965,000 | $8,461,000 | $5,336,000 | $795,000 |
| Inventory | $29,627,000 | $26,219,000 | $28,253,000 | $24,783,000 |
| Receivables | $217,451,000 | $109,861,000 | $81,999,000 | $89,450,000 |
| Accounts Receivable | $217,451,000 | $109,861,000 | $81,999,000 | $89,450,000 |
| Allowance For Doubtful Accounts Receivable | $-16,089,000 | $-9,576,000 | $-6,860,000 | $-6,362,000 |
| Gross Accounts Receivable | $233,540,000 | $119,437,000 | $88,859,000 | $95,812,000 |
| Cash Cash Equivalents And Short Term Investments | $93,679,000 | $135,571,000 | $103,840,000 | $102,478,000 |
| Cash And Cash Equivalents | $93,679,000 | $135,571,000 | $103,840,000 | $102,478,000 |
| Debt | ||||
| Total Debt | $82,137,000 | $43,312,000 | $119,351,000 | $123,791,000 |
| Long Term Debt And Capital Lease Obligation | $63,495,000 | $34,199,000 | $99,640,000 | $107,545,000 |
| Current Debt And Capital Lease Obligation | $18,642,000 | $9,113,000 | $19,711,000 | $16,246,000 |
| Long Term Debt | - | - | $60,745,000 | $66,231,000 |
| Current Debt | - | - | $5,486,000 | $4,538,000 |
| Other Current Borrowings | - | - | $5,486,000 | $4,538,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $164,812,000 | $112,570,000 | $181,362,000 | $183,690,000 |
| Total Non Current Liabilities Net Minority Interest | $64,688,000 | $35,093,000 | $100,853,000 | $108,667,000 |
| Other Non Current Liabilities | $1,193,000 | $894,000 | $1,213,000 | $1,122,000 |
| Current Liabilities | $100,124,000 | $77,477,000 | $80,509,000 | $75,023,000 |
| Other Current Liabilities | $1,260,000 | $1,450,000 | $1,087,000 | $926,000 |
| Current Deferred Liabilities | $3,861,000 | $0 | - | $0 |
| Payables And Accrued Expenses | $33,647,000 | $43,078,000 | $41,424,000 | $40,738,000 |
| Payables | $31,949,000 | $33,197,000 | $33,523,000 | $34,955,000 |
| Total Tax Payable | $0 | $4,286,000 | $2,799,000 | $2,625,000 |
| Accounts Payable | $31,949,000 | $28,911,000 | $30,724,000 | $32,330,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $300,129,000 | $262,897,000 | $278,663,000 | $265,669,000 |
| Preferred Stock Equity | $133,789,000 | $122,419,000 | - | - |
| Total Equity Gross Minority Interest | $433,918,000 | $385,316,000 | $278,663,000 | $265,669,000 |
| Stockholders Equity | $433,918,000 | $385,316,000 | $278,663,000 | $265,669,000 |
| Retained Earnings | $-3,078,000 | $-40,110,000 | $-40,971,000 | $-45,301,000 |
| Other | ||||
| Treasury Shares Number | $728,548 | $728,548 | $728,548 | $728,548 |
| Ordinary Shares Number | $126,951,876 | $125,730,236 | $131,316,396 | $130,919,129 |
| Share Issued | $127,680,424 | $126,458,784 | $132,044,944 | $131,647,677 |
| Tangible Book Value | $262,212,000 | $221,657,000 | $234,020,000 | $216,108,000 |
| Invested Capital | $300,129,000 | $262,897,000 | $344,894,000 | $336,438,000 |
| Working Capital | $262,064,000 | $208,464,000 | $144,535,000 | $147,586,000 |
| Capital Lease Obligations | $82,137,000 | $43,312,000 | $53,120,000 | $53,022,000 |
| Total Capitalization | $433,918,000 | $385,316,000 | $339,408,000 | $331,900,000 |
| Additional Paid In Capital | $303,194,000 | $302,994,000 | $319,621,000 | $310,957,000 |
| Capital Stock | $133,802,000 | $122,432,000 | $13,000 | $13,000 |
| Common Stock | $13,000 | $13,000 | $13,000 | $13,000 |
| Preferred Stock | $133,789,000 | $122,419,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $63,495,000 | $34,199,000 | $38,895,000 | $41,314,000 |
| Current Deferred Revenue | $3,861,000 | $0 | - | - |
| Current Capital Lease Obligation | $18,642,000 | $9,113,000 | $14,225,000 | $11,708,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $42,714,000 | $23,836,000 | $18,287,000 | $17,113,000 |
| Current Accrued Expenses | $1,698,000 | $9,881,000 | $7,901,000 | $5,783,000 |
| Goodwill | $28,772,000 | $28,772,000 | $28,772,000 | $28,772,000 |
| Net PPE | $159,460,000 | $126,238,000 | $156,346,000 | $145,655,000 |
| Accumulated Depreciation | $-88,107,000 | $-72,949,000 | $-73,186,000 | $-62,798,000 |
| Gross PPE | $247,567,000 | $199,187,000 | $229,532,000 | $208,453,000 |
| Leases | $67,866,000 | $63,342,000 | $60,819,000 | $37,607,000 |
| Construction In Progress | $26,743,000 | $21,887,000 | $59,067,000 | $65,564,000 |
| Other Properties | $83,725,000 | $37,110,000 | $40,118,000 | $43,192,000 |
| Machinery Furniture Equipment | $69,233,000 | $63,248,000 | $64,585,000 | $57,147,000 |
| Buildings And Improvements | $0 | $13,600,000 | $4,943,000 | $4,943,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $14,023,000 | $12,044,000 | $14,455,000 | $11,479,000 |
| Work In Process | $1,265,000 | $923,000 | $810,000 | $1,022,000 |
| Raw Materials | $14,339,000 | $13,252,000 | $12,988,000 | $12,282,000 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,460,000 | $4,176,000 | $6,553,000 | $-9,039,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,309,000 | $14,208,000 | $30,917,000 | $24,859,000 |
| Cash Flow From Continuing Operating Activities | $-10,309,000 | $14,208,000 | $30,917,000 | $24,859,000 |
| Operating Gains Losses | $188,000 | $1,355,000 | $235,000 | $4,482,000 |
| Investing Activities | ||||
| Capital Expenditure | $-14,151,000 | $-10,032,000 | $-24,364,000 | $-33,898,000 |
| Investing Cash Flow | $-14,151,000 | $-10,032,000 | $-24,364,000 | $-33,898,000 |
| Cash Flow From Continuing Investing Activities | $-14,151,000 | $-10,032,000 | $-24,364,000 | $-33,898,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-25,479,000 | $0 | $0 |
| Issuance Of Capital Stock | $0 | $120,688,000 | $0 | $0 |
| Financing Cash Flow | $-17,360,000 | $27,637,000 | $-5,505,000 | $-2,199,000 |
| Cash Flow From Continuing Financing Activities | $-17,360,000 | $27,637,000 | $-5,505,000 | $-2,199,000 |
| Net Other Financing Charges | $-16,346,000 | $-1,175,000 | $-332,000 | $-1,256,000 |
| Net Preferred Stock Issuance | $0 | $120,688,000 | $0 | $0 |
| Preferred Stock Issuance | $0 | $120,688,000 | $0 | $0 |
| Net Common Stock Issuance | $0 | $-25,479,000 | $0 | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-1,171,000 | $-67,644,000 | $-5,173,000 | $-3,013,000 |
| Interest Paid Supplemental Data | $0 | $4,970,000 | $5,436,000 | $2,649,000 |
| Income Tax Paid Supplemental Data | $5,346,000 | $6,965,000 | $3,052,000 | $1,201,000 |
| End Cash Position | $94,331,000 | $136,151,000 | $104,338,000 | $103,290,000 |
| Beginning Cash Position | $136,151,000 | $104,338,000 | $103,290,000 | $114,528,000 |
| Changes In Cash | $-41,820,000 | $31,813,000 | $1,048,000 | $-11,238,000 |
| Proceeds From Stock Option Exercised | $157,000 | $1,247,000 | $0 | $2,070,000 |
| Common Stock Payments | $0 | $-25,479,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-1,171,000 | $-67,644,000 | $-5,173,000 | $-3,013,000 |
| Net Long Term Debt Issuance | $-1,171,000 | $-67,644,000 | $-5,173,000 | $-3,013,000 |
| Long Term Debt Payments | $-1,171,000 | $-67,644,000 | $-5,173,000 | $-3,013,000 |
| Net PPE Purchase And Sale | $-14,151,000 | $-10,032,000 | $-24,364,000 | $-33,898,000 |
| Purchase Of PPE | $-14,151,000 | $-10,032,000 | $-24,364,000 | $-33,898,000 |
| Change In Working Capital | $-132,381,000 | $-48,889,000 | $-18,073,000 | $-34,082,000 |
| Change In Other Working Capital | $-8,491,000 | $-14,066,000 | $-8,439,000 | $-7,006,000 |
| Change In Other Current Liabilities | $158,000 | $-1,062,000 | $91,000 | $72,000 |
| Change In Payables And Accrued Expense | $9,853,000 | $6,792,000 | $3,030,000 | $-8,590,000 |
| Change In Accrued Expense | $10,381,000 | $9,164,000 | $3,138,000 | $-11,850,000 |
| Change In Payable | $-528,000 | $-2,372,000 | $-108,000 | $3,260,000 |
| Change In Account Payable | $-528,000 | $-2,372,000 | $-108,000 | $3,260,000 |
| Change In Prepaid Assets | $-183,000 | $-2,549,000 | $-10,115,000 | $-378,000 |
| Change In Inventory | $-17,915,000 | $-6,204,000 | $-8,179,000 | $-9,410,000 |
| Change In Receivables | $-115,803,000 | $-31,800,000 | $5,539,000 | $-8,770,000 |
| Changes In Account Receivables | $-115,803,000 | $-31,800,000 | $5,539,000 | $-8,770,000 |
| Other Non Cash Items | $15,728,000 | $8,909,000 | $8,056,000 | $10,583,000 |
| Stock Based Compensation | $13,298,000 | $10,578,000 | $8,996,000 | $6,552,000 |
| Provisionand Write Offof Assets | $8,213,000 | $3,938,000 | $1,297,000 | $1,781,000 |
| Asset Impairment Charge | $11,175,000 | $22,801,000 | $0 | $0 |
| Deferred Tax | $9,500,000 | $-10,719,000 | $2,012,000 | $1,980,000 |
| Deferred Income Tax | $9,500,000 | $-10,719,000 | $2,012,000 | $1,980,000 |
| Depreciation Amortization Depletion | $26,938,000 | $25,374,000 | $23,449,000 | $18,031,000 |
| Depreciation And Amortization | $26,938,000 | $25,374,000 | $23,449,000 | $18,031,000 |
| Amortization Cash Flow | $3,323,000 | $3,403,000 | $4,918,000 | $4,883,000 |
| Amortization Of Intangibles | $3,323,000 | $3,403,000 | $4,918,000 | $4,883,000 |
| Depreciation | $23,615,000 | $21,971,000 | $18,531,000 | $13,148,000 |
| Gain Loss On Sale Of PPE | $188,000 | $1,140,000 | $235,000 | $4,482,000 |
| Net Income From Continuing Operations | $37,032,000 | $861,000 | $4,945,000 | $15,532,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Net Intangibles Purchase And Sale | - | - | - | - |
| Purchase Of Intangibles | - | - | - | - |
Fetched: 2026-06-21